Oruka Therapeutics (NASDAQ:ORKA) and Guardian Pharmacy Services (NYSE:GRDN) Critical Review

Oruka Therapeutics (NASDAQ:ORKA) and Guardian Pharmacy Services (NYSE:GRDN) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Institutional & Insider Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. 24.7% of Oruka Therapeutics shares are owned by insiders. Comparatively, 63.7% of Guardian Pharmacy Services shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Oruka Therapeutics has a beta of -0.54, indicating that its share price is 154% less volatile than the S&P 500. Comparatively, Guardian Pharmacy Services has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oruka Therapeutics and Guardian Pharmacy Services, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1	0	10	0	2.82
Guardian Pharmacy Services	0	1	6	1	3.00

Oruka Therapeutics presently has a consensus price target of $64.90, indicating a potential upside of 4.66%. Guardian Pharmacy Services has a consensus price target of $39.20, indicating a potential downside of 2.01%. Given Oruka Therapeutics’ higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Guardian Pharmacy Services.

Profitability

This table compares Oruka Therapeutics and Guardian Pharmacy Services’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-25.48%	-24.34%
Guardian Pharmacy Services	3.40%	31.64%	16.03%

Valuation and Earnings

This table compares Oruka Therapeutics and Guardian Pharmacy Services”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43 million	($1.86)	-33.34
Guardian Pharmacy Services	$1.45 billion	1.75	$49.22 million	$0.77	51.95

Guardian Pharmacy Services has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

Summary

Guardian Pharmacy Services beats Oruka Therapeutics on 11 of the 14 factors compared between the two stocks.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.